Danaher Corporation (NYSE: DHR) released its financial results for the second quarter ended June 26, 2026, delivering top- and bottom-line figures that exceeded Wall Street consensus expectations. Consolidated revenues for the quarter reached $6.265 billion, representing a 5.5% year-over-year expansion relative to $5.936 billion reported in the second quarter of 2025. This top-line outcome surpassed analyst consensus estimates of $6.10 billion to $6.16 billion by approximately 3.3%. Non-GAAP adjusted diluted net earnings per share (EPS) grew 8.0% year-over-year to $1.94, outperforming consensus forecasts of $1.83 to $1.85 per share by $0.09 to $0.11.
Driven by strong second-quarter operational execution and the earlier-than-anticipated closure of the $2.8 billion acquisition of Masimo Corporation in early June 2026, corporate management raised its full-year 2026 non-GAAP adjusted diluted net EPS guidance to a range of $8.45 to $8.60, up from the prior guidance range of $8.35 to $8.55. Full-year non-GAAP core revenue growth expectations were reaffirmed at 3.0% to 4.0% year-over-year.
Despite these headline financial beats and elevated full-year profitability guidance, Danaher’s common stock experienced sharp pre-market selling pressure following the announcement, dropping 14.87% to $171.20 per share from its previous closing price of $201.11. Equity market participants focused heavily on customer-driven timing delays within the bioprocessing portfolio, where more than $100 million of high-margin chromatography resin shipments shifted out of the second half of 2026 into fiscal year 2027 due to client site-readiness schedules. This shipment shift, alongside a narrowed full-year core revenue growth outlook relative to early bull-case expectations, triggered valuation multiple compression despite underlying order intake strength.
| Financial Metric | Q2 2026 | Q2 2025 | YoY Change (%) | Consensus Estimate | Variance vs. Consensus |
| Total Revenue ($M) | $6,265 | $5,936 | +5.5% | $6,100 – $6,163 | +3.3% / +$102M to +$165M |
| GAAP Net Earnings ($M) | $870 | $555 | +56.8% | N/A | N/A |
| GAAP Diluted EPS ($) | $1.23 | $0.77 | +59.7% | N/A | N/A |
| Non-GAAP Adjusted EPS ($) | $1.94 | $1.80 | +8.0% | $1.83 – $1.85 | +$0.09 to +$0.11 (+6.0%) |
| Non-GAAP Core Sales Growth | +3.0% | +1.5% | +150 bps | ~+2.0% | +100 bps |
| Core Growth Ex-Respiratory Testing | +4.5% | +2.0% | +250 bps | ~+3.5% | +100 bps |
| Operating Cash Flow ($M) | $1,534 | N/A | N/A | N/A | N/A |
| Non-GAAP Free Cash Flow ($M) | $1,265 | N/A | N/A | N/A | N/A |
Comprehensive Q2 2026 Financial and Margin Performance
Danaher’s 5.5% reported revenue expansion in the second quarter was composed of 3.0% non-GAAP core revenue growth, a 1.5% net positive contribution from acquisitions, and a 1.0% favorable foreign currency translation tailwind. Excluding the predictable post-pandemic decline in Cepheid respiratory testing sales, core sales growth reached 4.5% year-over-year. This represents a 150 basis point acceleration from the first quarter of 2026, driven by continuous end-market recovery across life sciences instrument workflows and clinical diagnostics panels.
Gross profit for the quarter ended June 26, 2026, totaled $3.611 billion, producing a gross profit margin of 57.6%. This structural margin performance reflected favorable non-respiratory volume recovery, higher factory utilization, and sustained pricing power across key consumables workflows. Operational cost discipline under the Danaher Business System (DBS) was evident in selling, general, and administrative (SG&A) expenses, which decreased to $2.072 billion from $2.360 billion in the prior-year period, demonstrating operating leverage from recent organizational realignment actions. Research and development (R&D) investments were maintained at $412 million, representing 6.6% of revenue, ensuring steady funding for high-margin proprietary instrument platforms and assay menus.
On a GAAP basis, operating profit reached $1.127 billion, generating an operating margin of 18.0%, compared to $760 million, or a 12.8% operating margin, in the second quarter of 2025. Non-GAAP adjusted operating profit grew to $1.698 billion, yielding an adjusted operating margin of 27.1%. The slight 20 basis point year-over-year contraction in adjusted operating margin from 27.3% was caused primarily by integration expenses related to the Masimo transaction, business mix shifts, and lower high-margin respiratory testing volume compared to prior-year periods.
GAAP net earnings attributable to common shareholders rose 56.8% year-over-year to $870 million, or $1.23 per diluted common share. Non-GAAP adjusted net earnings expanded to $1.94 per diluted share. The adjustment bridge between GAAP diluted net EPS and non-GAAP adjusted diluted net EPS consists of $0.65 per share in amortization of acquisition-related intangible assets ($463 million total), $0.15 per share in acquisition-related transaction and integration costs ($108 million total), and $0.01 per share in unrealized fair value losses on equity investments.
| Consolidated Statement of Earnings ($M, except per share data) | Three Months Ended June 26, 2026 | Three Months Ended June 27, 2025 | Six Months Ended June 26, 2026 | Six Months Ended June 27, 2025 |
| Sales | $6,265 | $5,936 | $12,216 | $11,677 |
| Cost of Sales | $(2,654) | $(2,413) | $(5,123) | $(4,842) |
| Gross Profit | $3,611 | $3,523 | $7,093 | $6,835 |
| Selling, General & Administrative Expenses | $(2,072) | $(2,360) | $(3,932) | $(4,218) |
| Research & Development Expenses | $(412) | $(403) | $(799) | $(782) |
| Operating Profit | $1,127 | $760 | $2,471 | $2,034 |
| Other Income (Expense), Net | $(3) | $(42) | $(76) | $(121) |
| Interest Expense | $(107) | $(71) | $(170) | $(143) |
| Interest Income | $61 | $8 | $88 | $14 |
| Earnings Before Income Taxes | $1,078 | $655 | $2,313 | $1,784 |
| Income Taxes | $(208) | $(100) | $(414) | $(275) |
| Net Earnings | $870 | $555 | $1,899 | $1,509 |
| Basic Earnings Per Share ($) | $1.23 | $0.77 | $2.69 | $2.11 |
| Diluted Earnings Per Share ($) | $1.23 | $0.77 | $2.68 | $2.10 |
| Average Diluted Shares Outstanding (M) | 707.6 | 719.1 | 709.4 | 719.9 |
Segment Performance and Workstream Dynamics
Danaher organizes its commercial operations across three reportable segments: Diagnostics, Biotechnology, and Life Sciences. Total revenue generated in the second quarter of 2026 was led by Diagnostics at $2.47 billion, followed by Biotechnology at $1.92 billion and Life Sciences at $1.88 billion. Operational dynamics varied across these divisions, reflecting robust analytical instrument demand in Life Sciences, expanded non-respiratory molecular menu adoption in Diagnostics, and shipment timing delays offsetting strong order intakes in Biotechnology.
Segment Performance and Workstream Dynamics
Danaher organizes its commercial operations across three reportable segments: Diagnostics, Biotechnology, and Life Sciences. Total revenue generated in the second quarter of 2026 was led by Diagnostics at $2.47 billion, followed by Biotechnology at $1.92 billion and Life Sciences at $1.88 billion. Operational dynamics varied across these divisions, reflecting robust analytical instrument demand in Life Sciences, expanded non-respiratory molecular menu adoption in Diagnostics, and shipment timing delays offsetting strong order intakes in Biotechnology.
Biotechnology Segment
The Biotechnology segment, led by Cytiva, generated total sales of $1.92 billion in the second quarter. This represented a 4.0% GAAP revenue increase and 2.5% core sales growth year-over-year, offset by a 1.5% foreign currency translation headwind.
Demand across drug discovery and medical workflows grew at a mid-single-digit pace. Commercial order momentum remained strong across the segment, with bioprocessing orders increasing in the mid-teens across both single-use consumables and biomanufacturing equipment. However, realized revenue growth was limited by customer project delays. Specifically, concentrated site-readiness adjustments by commercial biopharma customers deferred over $100 million of chromatography resin deliveries out of the second half of 2026 into 2027. Management emphasized that these deferrals reflect facility construction and production scheduling shifts rather than project cancellations or broader demand softening. Operating margins within the segment remained stable at historically high levels due to cost controls.
Life Sciences Segment
The Life Sciences segment emerged as the top operational performer during the quarter, generating $1.88 billion in revenue. The division achieved core revenue growth of 5.5% year-over-year, marking its highest quarterly core growth rate in several years. Operating leverage from increased volume, paired with DBS productivity gains, delivered 210 basis points of core operating margin expansion.
Performance was broad-based across both capital equipment and recurring consumables. Applied filtration sales at Pall Corporation increased 10% year-over-year, while microelectronics filtration expanded 10% on strong demand for advanced semiconductor manufacturing and memory production workflows. Beckman Life Sciences and Abcam also delivered solid top-line results, benefiting from early stabilization in biotech capital funding and effective commercial execution.
Diagnostics Segment
The Diagnostics segment reported total revenue of $2.47 billion, representing 7.0% GAAP sales growth and 2.0% non-GAAP core revenue growth. Inorganic acquisitions contributed 4.0% to GAAP sales growth, offset by a 1.0% foreign currency translation drag. Excluding the headwind from Cepheid respiratory testing normalization, core sales growth reached 5.0% year-over-year.
Cepheid’s non-respiratory panel revenues grew in the low double-digits, driven by customer adoption of the GeneXpert platform for hospital-acquired infection (HAI) testing and the Multiplex Gastrointestinal (GI) assay. Respiratory testing revenue (COVID-19, Flu A/B, RSV) totaled $250 million for the quarter, down from $300 million in the second quarter of 2025, aligning with post-pandemic clinical testing baselines.
| Segment Revenue & Core Growth Summary | GAAP Sales Growth (Q2 ’26 vs. Q2 ’25) | Non-GAAP Core Sales Growth | Core Growth Ex-Respiratory | GAAP Sales Growth (H1 ’26 vs. H1 ’25) | Non-GAAP H1 Core Growth |
| Biotechnology | 4.0% | 2.5% | 2.5% | 7.5% | 4.5% |
| Life Sciences | 5.5% | 5.5% | 5.5% | 4.5% | 3.0% |
| Diagnostics | 7.0% | 2.0% | 5.0% | 2.5% | (1.0)% |
| Total Company | 5.5% | 3.0% | 4.5% | 4.5% | 2.0% |
